Subscribe To
CYTO / Altamira Therapeutics to Present at 2nd Annual mRNA-Based Therapeutics Summit Europe Conference January 24th to 26th
Content Topics
Altamira
Therapeutics
Present
Annual
Mrna
Based
Mrna based
Summit
Europe
Conference
January
Stock
CYTO
CYTO News
By InvestorPlace
November 3, 2023
Why Is Altamira Therapeutics (CYTO) Stock Up 28% Today?
Altamira Therapeutics (NASDAQ: CYTO ) stock is rising higher on Friday despite a lack of news from the biopharmaceutical company. There are no new pr more_horizontal
By Seeking Alpha
September 12, 2023
Altamira Therapeutics Ltd. (CYTO) Q2 2023 Earnings Call Transcript
Altamira Therapeutics Ltd. (NASDAQ:CYTO ) Q2 2023 Earnings Conference Call September 12, 2023 8:00 AM ET Company Participants Thomas Meyer - Founder, more_horizontal
By Seeking Alpha
May 18, 2023
Altamira Therapeutics Ltd. (CYTO) Q4 2022 Earnings Call Transcript
Altamira Therapeutics Ltd. (NASDAQ:CYTO ) Q4 2022 Earnings Conference Call May 16, 2023 8:00 AM ET Company Participants Thomas Meyer - Founder, Chairm more_horizontal
By InvestorPlace
May 4, 2023
Why Is Altamira Therapeutics (CYTO) Stock Up 45% Today?
Altamira Therapeutics (NASDAQ: CYTO ) stock is taking off on Thursday despite a lack of news from the RNA-based therapeutics company. There are no new more_horizontal
By Accesswire
May 1, 2023
Altamira Therapeutics CEO & Chairman to Present at Sidoti Micro-Cap Virtual Conference May 10-11
HAMILTON, BERMUDA / ACCESSWIRE / May 1, 2023 / Altamira Therapeutics ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing th more_horizontal
By InvestorPlace
April 12, 2023
Why Is Altamira Therapeutics (CYTO) Stock Up 64% Today?
Altamira Therapeutics (NASDAQ: CYTO ) stock is taking off on Wednesday after providing an update on its SemaPhore nanoparticle technology. According t more_horizontal
By Accesswire
February 14, 2023
Altamira Therapeutics to Report Bentrio Clinical Data, in House Dust Mite and Grass Pollen Allergic Rhinitis, at Feb. 25 AAAAI Annual Meet-ing
House dust mite study shows statistically significant reduction in symptoms vs. no protection Grass pollen study shows faster onset of action and supe more_horizontal
By Accesswire
February 7, 2023
Altamira Therapeutics to Present at Two Upcoming RNA Therapeutics Conferences in Q1 2023
New, trends and future of RNA-based therapeutics Company's OligoPhoreTM / SemaPhoreTM polyplexes provide for efficient delivery of siRNA payloads into more_horizontal